Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CYANOCOBALAMIN

All injection strengths: not a benefit

Other products in the same Health Canada class (B03B) — coverage varies; not interchangeable

  • Folic acid (Folvite): general benefit, Not a benefit

Rubramin · DIN 00029165 · 1mg/mL · injection solution-10mL Pk

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-08-09 — choose a marketed DIN from the same-category list.Discontinued 1999-08-09 · checked 2026-09-20
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-08-09 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1999-08-09 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Rubramin · DIN 00029165 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 1999-08-09 · brand RUBRAMIN 1000MCG/ML · ATC B03BA01 CYANOCOBALAMIN · form Liquid · route Intravenous, Subcutaneous, Intramuscular · ingredients VITAMIN B12 1 MG/ML · company Squibb canada inc., division of bristol-myers squibb canada inc. · schedule Ethical
Check this DIN again · Health Canada product record

Rubramin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=830 · Verify on the e-Formulary ↗ (DIN 00029165)

Source record
DIN 00029165: Rubramin Raw flags: notABenefit=Y, sec3=Y Item: 880800001; group id 880; item number 2121; lccId None; manufacturer id BQU Source form: Inj Sol-10mL Pk; strength: 1mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00029165 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=830
Interchangeable products
Cyanocobalamin · DIN 01987003 · $3.0600 Cyanocobalamin Injection USP · DIN 02413795 · $3.0600 Jamp-Cyanocobalamin · DIN 02420147 · $3.0600 Vitamin B12-1000mcg/mL · DIN 00521515 · $3.0600
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 1999-08-09 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (88:08 Vitamin B) and how they are covered

Matched class: 88:08 Vitamin B

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: LEUCOVORIN CALCIUM Some products covered without a code (check the product listing): FOLIC ACID 88:08 Vitamin B

FOLIC ACID

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 5mg · Tab

LEUCOVORIN CALCIUM

· 4 products · General benefit · strengths: 5mg · Tab

NICOTINIC ACID

· 2 products · Listed, not a benefit · strengths: 50mg · Tab

THIAMINE HCL

· 2 products · Listed, not a benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada · strengths: 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 88:08
Full class listing Related classes: 88:12 Vitamin C, 88:16 Vitamin D, 88:28 Multivitamins Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Vitamin B12 Deficiency: For vitamin B12 deficiency occurring in pernicious anemia with or without neurological complications. Other macrocytic, megaloblastic anemias where etiology suggests malabsorption of vitamin B12 such as following: gastrectomy, gastric carcinoma, megaloblastic anemia associated with such gastrointestinal disorders as sprue syndrome, blind loops and anastomoses and fish tapeworm. Note: In macrocytic megaloblastic anemia of pregnancy and sprue syndromes, cyanocobalamin may fail to produce satisfactory response, folic acid being indicated alone or in combination with cyanocobalamin. The injection is also suitable for use as the flushing dose in the Schilling (vitamin B12 absorption) test for pernicious anemia. https://pdf.hres.ca/dpd_pm/00084630.PDF PM date: MAY 05, 2026 Source product: VITAMIN B12; DIN 00521515; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Rubramin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026